Last updated: February 20, 2026
What is the current market status for NDC 65162-0785?
NDC 65162-0785 corresponds to Lutetium Lu 177 Dotatate (Lutetium-177 Dotatate), a radiopharmaceutical indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Its approval by the FDA was granted in August 2018.
Industry Position and Competitors
Lutetium Lu 177 Dotatate is a targeted radioligand therapy, part of the expanding theranostic market. Key competitors include:
- Indications: Peptide receptor radionuclide therapy (PRRT)
- Alternatives: Peptide receptor radionuclide therapy (PRRT) programs using other radiolabeled somatostatin analogs
Major players in the space:
| Company |
Product |
Market Share |
Notes |
| Advanced Accelerator Applications (Novartis) |
Lutetium Lu 177 Dotatate |
Leading |
First FDA-approved PRRT for neuroendocrine tumors |
| Novartis |
Peptide-based therapies |
Growing |
Focuses on expanding indications and pipeline |
Market Size and Growth Trends
2022 Market Valuation
- Estimated global market size: $350 million
- North American share: 80%
- European and Asian markets: 20%
Projected Growth
- Compound annual growth rate (CAGR): 12.7% (2023-2028)
- Key drivers:
- Increasing recognition of theranostics
- Rising incidence of neuroendocrine tumors (NETs)
- Expanded approved indications and off-label use
Incidence Data
- Neuroendocrine tumor cases per year: approximately 250,000 globally
- US estimate: 20,000–30,000 new cases annually
Price Projections for NDC 65162-0785
Current Pricing
- Average wholesale price (AWP) per treatment unit: $37,500
- Treatment course: Typically involves 4 infusions over 6-8 weeks
- Estimated per-patient cost: $150,000
Factors Influencing Price Trends
- Manufacturing costs: Slight decrease due to optimized production methods
- Market competition: Limited, as FDA approval is limited to a specific indication
- Reimbursement policies: Will significantly influence net pricing; Medicare and private payers require detailed coding and cost assessments
Future Pricing Projections (2023–2028)
| Year |
Anticipated Price Range per Treatment |
Rationale |
| 2023 |
$35,000 – $40,000 |
Price stabilization, high demand |
| 2024 |
$33,000 – $38,000 |
Slight pressure from reimbursement negotiations |
| 2025 |
$31,000 – $36,000 |
Potential price erosion due to increased competition or biosimilar development |
| 2026 |
$29,000 – $34,000 |
Market consolidation effects |
| 2027 |
$28,000 – $33,000 |
Further cost reductions and expanded indications |
Reimbursement and Policy Impact
- Centers of excellence and payers may drive discounts
- CDER regulations and increased CMS coverage could stabilize or reduce prices
- Price negotiations may result in discounts of 10–15% over baseline by 2026
Regulatory and R&D Outlook
- Additional indications in pancreatic and thymic neuroendocrine tumors are under clinical review.
- Biosimilars are unlikely within the next 4 years due to the complexity of radiopharmaceutical manufacturing.
- Promising pipeline drugs are in early development, with potential to threaten current market dynamics post-2028.
Summary
Lutetium Lu 177 Dotatate has a well-established niche within theranostics for neuroendocrine tumors. The market size remains limited but is growing at double-digit CAGR driven by increasing tumor detection and therapy adoption. Price projections indicate slight declines in unit costs over the next five years, influenced heavily by reimbursement policies and potential expansion into new indications.
Key Takeaways
- The 2022 global market for Lutetium Lu 177 Dotatate was valued at approximately $350 million.
- CAGR is forecasted at 12.7% through 2028.
- Current treatment costs hover around $150,000 per patient; prices are projected to decline slightly to $28,000–$36,000 per treatment by 2027.
- Limited competition exists, but biosimilar development and expanded indications could impact prices.
- Reimbursement policy uncertainties remain the primary price factor moving forward.
FAQs
-
What factors could accelerate price reductions for Lutetium Lu 177 Dotatate?
Market entry of biosimilars, reimbursement pressures, and increased competition from alternative therapies.
-
How significant is the potential for new indications to impact market size?
Expanding approvals into pancreatic and other neuroendocrine tumors could increase market size by up to 30%–50%.
-
What are the primary cost drivers for this radiopharmaceutical?
Radioisotope production, specialized manufacturing, and regulatory compliance.
-
How does reimbursement influence actual sale prices?
Reimbursement negotiations, coverage policies, and coding significantly impact net revenue, often resulting in discounts from list prices.
-
Are biosimilars a threat within the next decade?
Biosimilars are unlikely soon due to complex manufacturing and regulatory challenges but may emerge after 5–7 years if patents expire or new entrants develop comparable products.
References
[1] U.S. Food and Drug Administration. (2018). FDA approves lutetium Lu 177 dotatate for certain types of neuroendocrine tumors.
[2] MarketWatch. (2023). Global Theranostics Market Size & Trends.
[3] IQVIA. (2022). Radiopharmaceuticals Market Outlook.
[4] NIH. (2022). Epidemiology of Neuroendocrine Tumors.
[5] Evaluate Pharma. (2023). Drug Pricing & Market Dynamics.
